The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual and for the treatment and prevention of recurrence in an HSV seropositive individual.

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

The invention relates to application of totarol for production of a preparation for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment, and for prophylaxis and prevention of relapses of such inflammations. The invention includes also a pharmaceutical composition for treatment of vaginal mucous membrane inflammations of bacterial origin, for alleviation of symptoms in such a treatment and for prophylaxis and prevention of relapses of such inflammations, the composition containing from 75 to 95 parts by wt. of a cellulose derivative, from 0.5 to 5 parts by wt. of lactic acid, from 0.5 to 5 parts by wt. of a basic polymer, wherein the stoichiometric ratio of lactic acid to the basic polymer is comprised in the range of 1:1 to 8:1, and comprising totarol in an amount of 0.001 to 5 parts by wt. as the active substance.

The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.

Disclosed herein are contraceptive medical devices that include at least a polymeric ring, a porous barrier material and an injection molding guide, where the guide may be symmetrical and/or have one or a plurality of planar surfaces, where the device may optionally administer at least one active agent.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

The present invention relates to a vaginal drug delivery device configured to safely and effectively deliver a therapeutic formulation in the vagina at or near a desired target area for a specified time period.

A vaginal barrier device system and method for preventing entry of potentially contaminated fluid during immersion activities such as swimming or bathing, providing a secure fit, easy insertion and extraction, convenient cleaning, carrying, and storage, and avoiding irritation of the cervix or vaginal wall.

The invention relates to a personal care product for alleviating skin dryness, includes facial skin dryness, breast skin dryness and vulval dryness and for restoring vaginal flora, acidic pH in the vagina, and vaginal health. Embodiments of the personal care product include a formulation including at least about 83 wt. % plant-based glycerides; from about 0.05 wt. % to about 0.15 wt. % sodium hyaluronate; and from about 0.01 wt. % to about 1.5 wt. % sea buckthorn powder. Another embodiment includes a personal care product including at least 55 wt. % plant-based glycerides and from about 20 wt. % to about 42 wt. % sucrose. The personal care product may also include shea olein. The person care product is substantially free of added water, alcohol, synthetic chemical, anti-microbial agent, and synthetic hormone.

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.